IN THE TREATMENT OF ACUTE CORONARY SYNDROME
DECISIONS TODAY CAN
IMPACT A LIFE
BRILINTA CAN HELP
BEYOND 30 DAYS, BEYOND THE HOSPITAL,
BETTER EFFICACY THAN CLOPIDOGREL
AT 30 DAYS, BRILINTA plus aspirin reduced the primary
composite end point of cardiovascular (CV) death,
myocardial infarction (MI),* or stroke by 12% RRR†
(ARR‡ 0.6%) vs clopidogrel plus aspirin.1,2§
AT 12 MONTHS, BRILINTA plus aspirin significantly
reduced the primary composite end point by 16% RRR
(ARR 1.9%) vs clopidogrel plus aspirin. The difference
between treatments was driven by CV death and MI
with no difference in stroke.1§
IMPORTANT SAFETY INFORMATION ABOUT BRILINTA
WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
A. BLEEDING RISK
B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
• BRILINTA, like other antiplatelet agents, can cause
• Maintenance doses of aspirin above 100 mg
significant, sometimes fatal, bleeding
reduce the effectiveness of BRILINTA and should
be avoided. After any initial dose, use with aspirin
• Do not use BRILINTA in patients with active
75 mg - 100 mg per day
pathological bleeding or a history of intracranial
hemorrhage
CONTRAINDICATIONS
• Do not start BRILINTA in patients planned to undergo • BRILINTA is contraindicated in patients with a history
urgent coronary artery bypass graft surgery (CABG).
of intracranial hemorrhage and active pathological
When possible, discontinue BRILINTA at least 5 days
bleeding such as peptic ulcer or intracranial hemorrhage.
prior to any surgery
BRILINTA is contraindicated in patients with severe
hepatic impairment because of a probable increase
• Suspect bleeding in any patient who is hypotensive
in exposure; it has not been studied in these patients.
and has recently undergone coronary angiography,
Severe hepatic impairment increases the risk of
percutaneous coronary intervention (PCI), CABG, or
bleeding because of reduced synthesis of coagulation
other surgical procedures in the setting of BRILINTA
proteins. BRILINTA is also contraindicated in patients
• If possible, manage bleeding without discontinuing
with hypersensitivity (eg, angioedema) to ticagrelor
BRILINTA. Stopping BRILINTA increases the risk of
or any component of the product
subsequent cardiovascular events